261 related articles for article (PubMed ID: 22206743)
1. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
[TBL] [Abstract][Full Text] [Related]
2. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Yusuf AA; Howell BL; Powers CA; St Peter WL
Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
[TBL] [Abstract][Full Text] [Related]
3. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
4. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care.
Federman AD; Halm EA; Siu AL
Med Care; 2007 Feb; 45(2):109-15. PubMed ID: 17224772
[TBL] [Abstract][Full Text] [Related]
5. Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.
Kitchlu A; Clemens K; Gomes T; Hackam DG; Juurlink DN; Mamdani M; Manno M; Oliver MJ; Quinn RR; Suri RS; Wald R; Yan AT; Garg AX
Nephrol Dial Transplant; 2012 Apr; 27(4):1591-8. PubMed ID: 21873621
[TBL] [Abstract][Full Text] [Related]
6. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
7. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
8. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
9. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
[TBL] [Abstract][Full Text] [Related]
10. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
Moran A; Goldman L
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):606-7. PubMed ID: 18695697
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the low-income subsidy and cost-related nonadherence to drug therapies in Medicare Part D.
Wei II; Lloyd JT; Shrank WH
J Am Geriatr Soc; 2013 Aug; 61(8):1315-23. PubMed ID: 23889465
[TBL] [Abstract][Full Text] [Related]
12. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
13. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
14. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Tonelli M; Bohm C; Pandeya S; Gill J; Levin A; Kiberd BA
Am J Kidney Dis; 2001 Mar; 37(3):484-9. PubMed ID: 11228171
[TBL] [Abstract][Full Text] [Related]
15. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
Clin Ther; 2009 Oct; 31(10):2178-88; discussion 2150-1. PubMed ID: 19922889
[TBL] [Abstract][Full Text] [Related]
16. Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy.
Priest J; Buikema A; Engel-Nitz NM; Cook CL; Cantrell CR
Popul Health Manag; 2012 Apr; 15(2):101-12. PubMed ID: 22313439
[TBL] [Abstract][Full Text] [Related]
17. National assessment of Medicare prescription plan coverage gaps among patients with atrial fibrillation in the US.
Kim MH; Lin J; Kreilick C
Adv Ther; 2009 Aug; 26(8):784-94. PubMed ID: 19690820
[TBL] [Abstract][Full Text] [Related]
18. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
19. Medicare Part D: challenges for dialysis patients. Part 1.
Smith S; Witten B; Paykin C; Weiner S; Chianchiano D; St Peter WL
Nephrol News Issues; 2011 Nov; 25(12):38-40, 42, 44-5. PubMed ID: 22204167
[TBL] [Abstract][Full Text] [Related]
20. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.
Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown C
Clin Ther; 2013 Oct; 35(10):1513-1525.e1. PubMed ID: 24139423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]